ITF Press Release, January 21, 2020

Robert Farah has been provisionally suspended under Article 8.3.1(c) of the 2019 Tennis Anti-Doping Programme (the “Programme”), pending determination of the charge against him at a full hearing pursuant to Article 8 of the Programme.

Mr. Farah, a 32-year-old player from Colombia, provided a urine sample as part of an Out-of-Competition testing mission on 17 October 2019. That sample was sent to the World Anti-Doping Agency (“WADA”) accredited laboratory in Montreal, Canada for analysis, and was found to contain Boldenone and its metabolite. Boldenone is a Non-Specified substance, which is prohibited under category S1 of the 2019 WADA Prohibited List (Anabolic Agents), and therefore is also prohibited under the Programme. Positive tests for Non-Specified Substances carry a mandatory Provisional Suspension.

On 11 January 2020, Mr. Farah was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and was Provisionally Suspended with effect from 21 January 2020. Mr. Farah had (and retains) the right to apply to the Chair of the Independent Tribunal convened to hear his case why the Provisional Suspension should not be imposed, but has chosen not to exercise that right to date.